Denali Therapeutics Inc. DNLI Business Segments — Interest and other income, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s business segments — interest and other income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s business segments — interest and other income, net?
- Denali Therapeutics Inc. (DNLI) reported business segments — interest and other income, net of $8.91M in Q1 2026.
- How has Denali Therapeutics Inc.'s business segments — interest and other income, net changed year-over-year?
- Denali Therapeutics Inc.'s business segments — interest and other income, net decreased by 29.3% year-over-year, from $12.61M to $8.91M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — interest and other income, net?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — interest and other income, net has grown at a 42.7% compound annual growth rate (CAGR), from $14.77M to $42.9M.
- What does business segments — interest and other income, net mean?
- Includes interest earned on cash and investment balances, as well as other non-operating gains or losses. This metric reflects the company's ability to generate returns on its capital reserves or other non-core activities. It provides a secondary source of liquidity that can help offset operational losses.